Company: SMNR
Filing Date: 2025-12-03
Form Type: S-8
Source: 0001193125-25-306969
Chunk: 4

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-12-03
Form: S-8
Chunk 4
---
, officers, employees and other agents to the maximum extent permitted by the DGCL, and the Registrant’s bylaws (the “Bylaws”) provide that the Registrant will indemnify its directors and officers and permit the Registrant to indemnify its employees and other agents, in each case to the extent not prohibited by the DGCL or any other applicable law. II-2

The Registrant has entered, and expects to continue to enter, into indemnification agreements with its directors and officers, that may be broader than the specific indemnification provisions contained in the DGCL. These agreements, among other things, require the Registrant to indemnify its directors and officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. The Registrant also maintains directors’ and officers’ liability insurance. ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED. Not applicable. ITEM 8. EXHIBITS.

| Exhibit 
 Number  
 4.1     
 4.2     |     | Description                                                                                                                                                        
 Restated Certificate of Incorporation of Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit                                                        
 3.1 to the Current Report on Form 8-K filed by the Registrant on September 26, 2025).                                                                              
 Bylaws of Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K filed by the Registrant on September 26, 2025). |
|:--------|:----|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5.1*    |     | Opinion of Paul Hastings LLP.                                                                                                                                      |
| 23.1*   |     | Consent of Pipara & Co LLP, independent registered public accounting firm of Semnur Pharmaceuticals, Inc.                                                          |
| 23.2*   |     | Consent of Paul Hastings LLP (included in Exhibit 5.1).                                                                                                            |
| 24.1*   |     | Power of Attorney is contained on the signature page.                                                                                                              |
| 99.1*   |     | Form of Semnur Pharmaceuticals, Inc. 2025 Equity Incentive Plan.                                                                                                   |
| 99.2*   |     | Form of Stock Option Grant Notice and Stock Option Agreement under the Semnur Pharmaceuticals, Inc. 2025